CoChat
Sign Up
Cited by 59Alzheimer's disease research and treatmentsDementia and Cognitive Impairment ResearchCholinesterase and Neurodegenerative Diseases

Chronic Memantine Treatment Ameliorates Behavioral Deficits, Neuron Loss, and Impaired Neurogenesis in a Model of Alzheimer’s Disease

Open access
Stazi, Martina, Wirths, Oliver·2021·Molecular Neurobiology
DOI 10.1007/s12035-020-02120-zPMC PMC7695672
Open this paper in CoChat — free accountOpen PDF

Abstract

Memantine, a non-competitive NMDA receptor antagonist possessing neuroprotective properties, belongs to the small group of drugs which have been approved for the treatment of Alzheimer’s disease (AD). While several preclinical studies employing different transgenic AD mouse models have described beneficial effects with regard to rescued behavioral deficits or reduced amyloid plaque pathology, it is largely unknown whether memantine might have beneficial effects on neurodegeneration. In the current study, we assessed whether memantine treatment has an impact on hippocampal neuron loss and associated behavioral deficits in the Tg4-42 mouse model of AD. We demonstrate that a chronic oral memantine treatment for 4 months diminishes hippocampal CA1 neuron loss and rescues learning and memory performance in different behavioral paradigms, such as Morris water maze or a novel object recognition task. Cognitive benefits of chronic memantine treatment were accompanied by an amelioration of impaired adult hippocampal neurogenesis. Taken together, our results demonstrate that memantine successfully counteracts pathological alterations in a preclinical mouse model of AD.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1007/s12035-020-02120-z

Cites

7 of 7 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

Research works printed but not linked: 61

  1. [1]Querfurth HW LaFerla FM Alzheimer’s disease N Engl J Med 2010 362 4 329 344 10.1056/NEJMra0909142 20107219 · DOI · Paper page
  2. [2]Goedert M Spillantini MG A century of Alzheimer’s disease Science 2006 314 5800 777 781 10.1126/science.1132814 17082447 · DOI
  3. [3]Anand A Patience AA Sharma N Khurana N The present and future of pharmacotherapy of Alzheimer’s disease: a comprehensive review Eur J Pharmacol 2017 815 364 375 10.1016/j.ejphar.2017.09.043 28978455 · DOI · Paper page
  4. [4]Reisberg B Doody R Stöffler A Schmitt F Ferris S Möbius HJ Memantine in moderate-to-severe Alzheimer’s disease N Engl J Med 2003 348 14 1333 1341 10.1056/NEJMoa013128 12672860 · DOI · Paper page
  5. [5]Lipton SA Paradigm shift in neuroprotection by NMDA receptor blockade: memantine and beyond Nat Rev Drug Discov 2006 5 2 160 170 10.1038/nrd1958 16424917 · DOI · Paper page
  6. [6]Parsons CG Stoffler A Danysz W Memantine: a NMDA receptor antagonist that improves memory by restoration of homeostasis in the glutamatergic system-too little activation is bad, too much is even worse Neuropharmacology 2007 53 6 699 723 10.1016/j.neuropharm.2007.07.013 17904591 · DOI
  7. [7]Erdö SL Schäfer M Memantine is highly potent in protecting cortical cultures against excitotoxic cell death evoked by glutamate and N-methyl-D-aspartate Eur J Pharmacol 1991 198 2 215 217 10.1016/0014-2999(91)90625-Z 1864308 · DOI
  8. [8]Weller M Marini AM Finiels-Marlier F Martin B Paul SM MK-801 and memantine protect cultured neurons from glutamate toxicity induced by glutamate carboxypeptidase-mediated cleavage of methotrexate Eur J Pharmacol 1993 248 4 303 312 10.1016/0926-6917(93)90004-a 7910141 · DOI
  9. [9]Kutzing MK Luo V Firestein BL Protection from glutamate-induced excitotoxicity by memantine Ann Biomed Eng 2012 40 5 1170 1181 10.1007/s10439-011-0494-z 22203191 PMC4217523 · DOI
  10. [10]Miguel-Hidalgo JJ Alvarez XA Cacabelos R Quack G Neuroprotection by memantine against neurodegeneration induced by β-amyloid(1–40) Brain Res 2002 958 1 210 221 10.1016/S0006-8993(02)03731-9 12468047 · DOI
  11. [11]Wenk GL Zajaczkowski W Danysz W Neuroprotection of acetylcholinergic basal forebrain neurons by memantine and neurokinin B Behav Brain Res 1997 83 1 129 133 10.1016/S0166-4328(97)86056-1 9062671 · DOI
  12. [12]Van Dam D De Deyn PP Cognitive evaluation of disease-modifying efficacy of galantamine and memantine in the APP23 model Eur Neuropsychopharmacol 2006 16 1 59 69 10.1016/j.euroneuro.2005.06.005 16095884 · DOI
  13. [13]Minkeviciene R Banerjee P Tanila H Memantine improves spatial learning in a transgenic mouse model of Alzheimer’s disease J Pharmacol Exp Ther 2004 311 2 677 682 10.1124/jpet.104.071027 15192085 · DOI
  14. [14]Scholtzova H Wadghiri YZ Douadi M Sigurdsson EM Li Y-S Quartermain D Banerjee P Wisniewski T Memantine leads to behavioral improvement and amyloid reduction in Alzheimer’s-disease-model transgenic mice shown as by micromagnetic resonance imaging J Neurosci Res 2008 86 12 2784 2791 10.1002/jnr.21713 18615702 PMC2723808 · DOI
  15. [15]Martinez-Coria H Green KN Billings LM Kitazawa M Albrecht M Rammes G Parsons CG Gupta S Banerjee P LaFerla FM Memantine improves cognition and reduces Alzheimer’s-like neuropathology in transgenic mice Am J Pathol 2010 176 2 870 880 10.2353/ajpath.2010.090452 20042680 PMC2808092 · DOI
  16. [16]Liu MY Wang S Yao WF Zhang ZJ Zhong X Sha L He M Zheng ZH Wei MJ Memantine improves spatial learning and memory impairments by regulating NGF signaling in APP/PS1 transgenic mice Neuroscience 2014 273 141 151 10.1016/j.neuroscience.2014.05.011 24846616 · DOI
  17. [17]Zhou X Wang L Xiao W Su Z Zheng C Zhang Z Wang Y Xu B Yang X Hoi MPM Memantine improves cognitive function and alters hippocampal and cortical proteome in triple transgenic mouse model of Alzheimer’s disease Exp Neurobiol 2019 28 3 390 403 10.5607/en.2019.28.3.390 31308798 PMC6614075 · DOI
  18. [18]Bouter Y Dietrich K Wittnam JL Rezaei-Ghaleh N Pillot T Papot-Couturier S Lefebvre T Sprenger F Wirths O Zweckstetter M Bayer TA N-truncated amyloid β (Aβ) 4-42 forms stable aggregates and induces acute and long-lasting behavioral deficits Acta Neuropathol 2013 126 2 189 205 10.1007/s00401-013-1129-2 23685882 PMC3722453 · DOI · Paper page
  19. [19]Antonios G Borgers H Richard BC Brauß A Meißner J Weggen S Pena V Pillot T Davies SL Bakrania P Matthews D Brownlees J Bouter Y Bayer TA Alzheimer therapy with an antibody against N-terminal Abeta 4-X and pyroglutamate Abeta 3-X Sci Rep 2015 5 17338 10.1038/srep17338 26626428 PMC4667289 · DOI · Paper page
  20. [20]Mullane K Williams M Preclinical models of Alzheimer’s disease: relevance and translational validity Curr Protoc Pharmacol 2019 84 1 e57 10.1002/cpph.57 30802363 · DOI
  21. [21]Gerberding AL Zampar S Stazi M Liebetanz D Wirths O Physical activity ameliorates impaired hippocampal neurogenesis in the Tg4-42 mouse model of Alzheimer’s disease ASN Neuro 2019 11 1759091419892692 10.1177/1759091419892692 31818124 PMC6906584 · DOI
  22. [22]Alley GM Bailey JA Chen D Ray B Puli LK Tanila H Banerjee PK Lahiri DK Memantine lowers amyloid-β peptide levels in neuronal cultures and in APP/PS1 transgenic mice J Neurosci Res 2010 88 1 143 154 10.1002/jnr.22172 19642202 PMC2783840 · DOI
  23. [23]Dong H Yuede CM Coughlan C Lewis B Csernansky JG Effects of memantine on neuronal structure and conditioned fear in the Tg2576 mouse model of Alzheimer’s disease Neuropsychopharmacology 2008 33 13 3226 3236 10.1038/npp.2008.53 18418360 PMC2664647 · DOI
  24. [24]Shiotsuki H Yoshimi K Shimo Y Funayama M Takamatsu Y Ikeda K Takahashi R Kitazawa S Hattori N A rotarod test for evaluation of motor skill learning J Neurosci Methods 2010 189 2 180 185 10.1016/j.jneumeth.2010.03.026 20359499 · DOI · Paper page
  25. [26]Karl T Pabst R von Horsten S Behavioral phenotyping of mice in pharmacological and toxicological research Exp Toxicol Pathol 2003 55 1 69 83 10.1078/0940-2993-00301 12940631 · DOI
  26. [27]Antunes M Biala G The novel object recognition memory: neurobiology, test procedure, and its modifications Cogn Process 2012 13 2 93 110 10.1007/s10339-011-0430-z 22160349 PMC3332351 · DOI · Paper page
  27. [28]Leger M Quiedeville A Bouet V Haelewyn B Boulouard M Schumann-Bard P Freret T Object recognition test in mice Nat Protoc 2013 8 12 2531 2537 10.1038/nprot.2013.155 24263092 · DOI · Paper page
  28. [29]Morris R Developments of a water-maze procedure for studying spatial learning in the rat J Neurosci Methods 1984 11 1 47 60 10.1016/0165-0270(84)90007-4 6471907 · DOI · Paper page
  29. [30]Saul A Sprenger F Bayer TA Wirths O Accelerated tau pathology with synaptic and neuronal loss in a novel triple transgenic mouse model of Alzheimer’s disease Neurobiol Aging 2013 34 11 2564 2573 10.1016/j.neurobiolaging.2013.05.003 23747045 · DOI · Paper page
  30. [31]Cotel MC Jawhar S Christensen DZ Bayer TA Wirths O Environmental enrichment fails to rescue working memory deficits, neuron loss, and neurogenesis in APP/PS1KI mice Neurobiol Aging 2012 33 1 96 107 10.1016/j.neurobiolaging.2010.02.012 20359774 · DOI
  31. [33]Raina P Santaguida P Ismaila A Patterson C Cowan D Levine M Booker L Oremus M Effectiveness of cholinesterase inhibitors and memantine for treating dementia: evidence review for a clinical practice guideline Ann Intern Med 2008 148 5 379 397 10.7326/0003-4819-148-5-200803040-00009 18316756 · DOI · Paper page
  32. [35]Wirths O Zampar S Emerging roles of N- and C-terminally truncated Aβ species in Alzheimer’s disease Expert Opin Ther Targets 2019 23 12 991 1004 10.1080/14728222.2019.1702972 31814468 · DOI · Paper page
  33. [37]Neumeister KL Riepe MW Synergistic effects of antidementia drugs on spatial learning and recall in the APP23 transgenic mouse model of Alzheimer’s disease J Alzheimers Dis 2012 30 2 245 251 10.3233/jad-2012-111643 22414570 · DOI
  34. [38]Filali M Lalonde R Rivest S Subchronic memantine administration on spatial learning, exploratory activity, and nest-building in an APP/PS1 mouse model of Alzheimer’s disease Neuropharmacology 2011 60 6 930 936 10.1016/j.neuropharm.2011.01.035 21281652 · DOI
  35. [39]Devi L Ohno M Cognitive benefits of memantine in Alzheimer’s 5XFAD model mice decline during advanced disease stages Pharmacol Biochem Behav 2016 144 60 66 10.1016/j.pbb.2016.03.002 26948858 · DOI
  36. [40]Morrissette DA Parachikova A Green KN LaFerla FM Relevance of transgenic mouse models to human Alzheimer disease J Biol Chem 2009 284 10 6033 6037 10.1074/jbc.R800030200 18948253 · DOI
  37. [41]Sasaguri H Nilsson P Hashimoto S Nagata K Saito T De Strooper B Hardy J Vassar R Winblad B Saido TC APP mouse models for Alzheimer’s disease preclinical studies EMBO J 2017 36 17 2473 2487 10.15252/embj.201797397 28768718 PMC5579350 · DOI · Paper page
  38. [42]Balducci C Forloni G APP transgenic mice: their use and limitations NeuroMolecular Med 2011 13 2 117 137 10.1007/s12017-010-8141-7 21152995 · DOI · Paper page
  39. [43]Ito K Tatebe T Suzuki K Hirayama T Hayakawa M Kubo H Tomita T Makino M Memantine reduces the production of amyloid-β peptides through modulation of amyloid precursor protein trafficking Eur J Pharmacol 2017 798 16 25 10.1016/j.ejphar.2017.02.001 28167259 · DOI
  40. [44]Jürgenson M Zharkovskaja T Noortoots A Morozova M Beniashvili A Zapolski M Zharkovsky A Effects of the drug combination memantine and melatonin on impaired memory and brain neuronal deficits in an amyloid-predominant mouse model of Alzheimer’s disease J Pharm Pharmacol 2019 71 11 1695 1705 10.1111/jphp.13165 31531878 · DOI
  41. [45]Stubley-Weatherly L Harding JW Wright JW Effects of discrete kainic acid-induced hippocampal lesions on spatial and contextual learning and memory in rats Brain Res 1996 716 1 29 38 10.1016/0006-8993(95)01589-2 8738217 · DOI
  42. [47]Masurkar AV Towards a circuit-level understanding of hippocampal CA1 dysfunction in Alzheimer’s disease across anatomical axes J Alzheimers Dis Parkinsonism 2018 8 1 412 10.4172/2161-0460.1000412 29928558 PMC6005196 · DOI · Paper page
  43. [48]Burke SN Maurer AP Nematollahi S Uprety AR Wallace JL Barnes CA The influence of objects on place field expression and size in distal hippocampal CA1 Hippocampus 2011 21 7 783 801 10.1002/hipo.20929 21365714 PMC3314262 · DOI
  44. [49]Ito HT Schuman EM Functional division of hippocampal area CA1 via modulatory gating of entorhinal cortical inputs Hippocampus 2012 22 2 372 387 10.1002/hipo.20909 21240920 PMC3627339 · DOI
  45. [50]Wilson DIG Langston RF Schlesiger MI Wagner M Watanabe S Ainge JA Lateral entorhinal cortex is critical for novel object-context recognition Hippocampus 2013 23 5 352 366 10.1002/hipo.22095 23389958 PMC3648979 · DOI
  46. [52]Buchman AS Bennett DA Loss of motor function in preclinical Alzheimer’s disease Expert Rev Neurother 2011 11 5 665 676 10.1586/ern.11.57 21539487 PMC3121966 · DOI · Paper page
  47. [53]Wirths O Bayer TA Motor impairment in Alzheimer’s disease and transgenic Alzheimer’s disease mouse models Genes Brain Behav 2008 7 Suppl 1 1 5 10.1111/j.1601-183X.2007.00373.x 18184365 · DOI
  48. [54]Wagner JM Sichler ME Schleicher EM Franke TN Irwin C Löw MJ Beindorff N Bouter C Bayer TA Bouter Y Analysis of motor function in the Tg4-42 mouse model of Alzheimer’s disease Front Behav Neurosci 2019 13 107 10.3389/fnbeh.2019.00107 31156407 PMC6533559 · DOI
  49. [55]Rueda N Llorens-Martin M Florez J Valdizan E Banerjee P Trejo JL Martinez-Cue C Memantine normalizes several phenotypic features in the Ts65Dn mouse model of Down syndrome J Alzheimers Dis 2010 21 1 277 290 10.3233/jad-2010-100240 20421694 · DOI
  50. [56]Joo I-S Hwang D-H Seok J-I Shin S-K Kim S-U Oral administration of memantine prolongs survival in a transgenic mouse model of amyotrophic lateral sclerosis J Clin Neurol 2007 3 4 181 186 10.3988/jcn.2007.3.4.181 19513129 PMC2686946 · DOI
  51. [57]S-i O Pouladi MA Talantova M Yao D Xia P Ehrnhoefer DE Zaidi R Clemente A Kaul M Graham RK Zhang D Vincent Chen HS Tong G Hayden MR Lipton SA Balance between synaptic versus extrasynaptic NMDA receptor activity influences inclusions and neurotoxicity of mutant huntingtin Nat Med 2009 15 12 1407 1413 10.1038/nm.2056 19915593 PMC2789858 · DOI
  52. [58]Ondo WG Mejia NI Hunter CB A pilot study of the clinical efficacy and safety of memantine for Huntington’s disease Parkinsonism Relat Disord 2007 13 7 453 454 10.1016/j.parkreldis.2006.08.005 17046312 · DOI
  53. [59]Stanley JL Lincoln RJ Brown TA McDonald LM Dawson GR Reynolds DS The mouse beam walking assay offers improved sensitivity over the mouse rotarod in determining motor coordination deficits induced by benzodiazepines J Psychopharmacol 2005 19 3 221 227 10.1177/0269881105051524 15888506 · DOI
  54. [60]Castaneda MT Lopez ED Touhami A Tovar R Ortega MR Rodriguez JM Neuroprotection of medial septal cholinergic neurons by memantine after intralateral septal injection of Aβ1–40 NeuroReport 2015 26 8 450 454 10.1097/wnr.0000000000000364 25919992 · DOI
  55. [61]Nyakas C Granic I Halmy LG Banerjee P Luiten PGM The basal forebrain cholinergic system in aging and dementia. Rescuing cholinergic neurons from neurotoxic amyloid-β42 with memantine Behav Brain Res 2011 221 2 594 603 10.1016/j.bbr.2010.05.033 20553766 · DOI
  56. [62]Wirths O Bayer TA Intraneuronal Abeta accumulation and neurodegeneration: lessons from transgenic models Life Sci 2012 91 23–24 1148 1152 10.1016/j.lfs.2012.02.001 22401905 · DOI
  57. [63]Wirths O Altered neurogenesis in mouse models of Alzheimer disease Neurogenesis 2017 4 1 e1327002 10.1080/23262133.2017.1327002 29564360 PMC5856097 · DOI
  58. [64]Jin K Xie L Mao XO Greenberg DA Alzheimer’s disease drugs promote neurogenesis Brain Res 2006 1085 1 183 188 10.1016/j.brainres.2006.02.081 16580645 · DOI
  59. [65]Maekawa M Namba T Suzuki E Yuasa S Kohsaka S Uchino S NMDA receptor antagonist memantine promotes cell proliferation and production of mature granule neurons in the adult hippocampus Neurosci Res 2009 63 4 259 266 10.1016/j.neures.2008.12.006 19367785 · DOI
  60. [67]Ishikawa R Uchida C Kitaoka S Furuyashiki T Kida S Improvement of PTSD-like behavior by the forgetting effect of hippocampal neurogenesis enhancer memantine in a social defeat stress paradigm Mol Brain 2019 12 1 68 10.1186/s13041-019-0488-6 31370877 PMC6676601 · DOI
  61. [68]Ishikawa R Kim R Namba T Kohsaka S Uchino S Kida S Time-dependent enhancement of hippocampus-dependent memory after treatment with memantine: implications for enhanced hippocampal adult neurogenesis Hippocampus 2014 24 7 784 793 10.1002/hipo.22270 24599753 · DOI

Cited by

Sorted by citations

Authors
Stazi, M., & Wirths, O.
Affiliations
Universitätsmedizin Göttingen (DE)
Corresponding author
Wirths, Oliver
ORCID
Venue
Molecular Neurobiology
Publisher
Springer Science and Business Media LLC
Published
2020-09-10
Volume
58
Issue
1
Pages
204-216
ISSN
  • 0893-7648 (ISSN-L)
  • 1559-1182
DOI
10.1007/s12035-020-02120-z
PMC
PMC7695672
OpenAlex
W3085091539
Cited by
59
References
7
Citations by year
2026: 8 · 2025: 13 · 2024: 8 · 2023: 12 · 2022: 7 · 2021: 11
FWCI
4.51
Type
journal article
Language
en
Open access
Licence
Locations
  • Molecular Neurobiology (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • Informationszentrum Lebenswissenschaften (ZB MED) (submittedVersion, cc-by)
  • GoeScholar The Publication Server of the Georg-August-Universität Göttingen (Georg-August-Universität Göttingen) (submittedVersion, cc-by)
Funders
Gerhard Hunsmann Stiftung
Topics
  • Health Sciences › Medicine › Physiology › Alzheimer's disease research and treatments
  • Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
  • Health Sciences › Medicine › Pharmacology › Cholinesterase and Neurodegenerative Diseases
Keywords
memantine, Alzheimer's disease, NMDA receptor antagonists, neuroprotection, hippocampal neuronal loss, CA1 neurons, adult hippocampal neurogenesis, learning and memory impairment, amyloid plaques, neurodegeneration
MeSH terms
Open Field Test, Administration, Oral, Alzheimer Disease, Animals, Anxiety, Behavior, Animal, Disease Models, Animal, Memantine, Mice, Transgenic, Motor Activity, Neurons, Neurogenesis, CA1 Region, Hippocampal, Spatial Memory

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review